American Research & Management Company’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

American Research & Management Company’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$384K	Sell	4,847 -150	-3%	-$12.6K	0.11%	89
2022 Q2	$371K	Hold	4,997	–	–	0.1%	95
2022 Q1	$449K	Buy	4,997 +14	+0.3%	+$1.29K	0.1%	94
2021 Q4	$558K	Hold	4,983	–	–	0.12%	87
2021 Q3	$626K	Hold	4,983	–	–	0.14%	82
2021 Q2	$675K	Sell	4,983 -1,425	-22%	-$187K	0.15%	79
2021 Q1	$869K	Hold	6,408	–	–	0.21%	73
2020 Q4	$902K	Hold	6,408	–	–	0.23%	72
2020 Q3	$714K	Sell	6,408 -50	-0.8%	-$5.61K	0.21%	71
2020 Q2	$723K	Buy	6,458 +3	+0%	+$295	0.22%	73
2020 Q1	$500K	Sell	6,455 -150	-2%	-$13.3K	0.19%	82
2019 Q4	$628K	Hold	6,605	–	–	0.19%	82
2019 Q3	$504K	Sell	6,605 -190	-3%	-$15.8K	0.15%	95
2019 Q2	$596K	Hold	6,795	–	–	0.18%	92
2019 Q1	$615K	Sell	6,795 -60	-0.9%	-$5.1K	0.18%	91
2018 Q4	$492K	Buy	6,855 +550	+9%	+$44.3K	0.17%	92
2018 Q3	$604K	Hold	6,305	–	–	0.18%	92
2018 Q2	$600K	Buy	6,305 +35	+0.6%	+$3.22K	0.21%	82
2018 Q1	$550K	Sell	6,270 -60	-0.9%	-$5.48K	0.18%	84
2017 Q4	$537K	Sell	6,330 -640	-9%	-$53.6K	0.17%	92
2017 Q3	$603K	Hold	6,970	–	–	0.2%	80
2017 Q2	$538K	Hold	6,970	–	–	0.18%	83
2017 Q1	$483K	Sell	6,970 -3,025	-30%	-$203K	0.17%	77
2016 Q4	$592K	Sell	9,995 -16,020	-62%	-$989K	0.2%	77
2016 Q3	$1.73M	Sell	26,015 -990	-4%	-$61.2K	0.63%	47
2016 Q2	$1.46M	Sell	27,005 -1,345	-5%	-$73.7K	0.56%	51
2016 Q1	$1.47M	Buy	28,350 +800	+3%	+$41.6K	0.62%	48
2015 Q4	$1.93M	Buy	27,550 +2,510	+10%	+$171K	0.83%	39
2015 Q3	$1.56M	Buy	25,040 +4,910	+24%	+$387K	0.68%	47
2015 Q2	$1.69M	Buy	20,130 +17,370	+629%	+$1.35M	0.69%	48
2015 Q1	$207K	Buy	2,760 +2,400	+667%	+$168K	0.08%	107
2014 Q4	$22K	Buy	360 +300	+500%	+$17.1K	0.01%	229
2014 Q3	$3K	Hold	60	–	–	﹤0.01%	347
2014 Q2	$3K	Buy	+60	New	+$2.71K	﹤0.01%	357

Other funds holding XBI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

American Research & Management Company's XBI Position: Q3 2022 in Review

American Research & Management Company reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 3% in Q3 2022, selling an estimated $12.6K and leaving 4,847 shares worth $384K. The position accounts for 0.11% of the portfolio, ranked #89.

American Research & Management Company first reported a position in XBI in Q2 2014 and has held it in 34 quarters since. The position peaked at $1.93M in Q4 2015. 703 funds tracked by Wall St. Rank hold XBI as of Q3 2022.

American Research & Management Company held 4,847 shares of State Street SPDR S&P Biotech ETF worth $384K as of Q3 2022.
American Research & Management Company sold 150 State Street SPDR S&P Biotech ETF shares in Q3 2022, an estimated $12.6K.
State Street SPDR S&P Biotech ETF made up 0.11% of American Research & Management Company's portfolio in Q3 2022, its #89 holding.
American Research & Management Company first reported a position in State Street SPDR S&P Biotech ETF in Q2 2014 and has held it in 34 quarters since.
American Research & Management Company's State Street SPDR S&P Biotech ETF position peaked at $1.93M in Q4 2015.
703 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2022.

Based on American Research & Management Company's 13F filing for Q3 2022, filed 7 Oct 2022.